ReviewMedicina (Kaunas, Lithuania)2025
The PitNET Puzzle: From Zero to Linking Molecular Behavior with Neurosurgical Aspects.
Review in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma.Pituitary · 2026Article
- Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pituitary gland is considered the conductor of the hormonal orchestra, and despite its small dimensions, numerous tumoral lesions can arise within it. Over the past decade, substantial changes have been made regarding the nomenclature, which are summarized in the 5th Edition of the World Health Organization Classification of Endocrine and Neuroendocrine Tumors. Furthermore, significant breakthroughs in biomolecular mechanisms have been uncovered, which have formed the basis for the new classification. The management of these lesions varies according to several factors such as tumoral dimensions, hormonal activity, symptomatology, and radiological findings. At the same time, the therapeutic goal is represented by normalization of hormonal hypersecretion if present, control of tumoral growth and/or relief of mass effect symptoms, and preservation or restoration of the pituitary function. The current narrative review aims to explore the link between biomolecular aspects, the extent of resectability, and the postoperative outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.